Brief: Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
09/05/2024 14:10
May 9 (Reuters) - Akoya Biosciences Inc AKYA.O :
* AKOYA BIOSCIENCES AND NERACARE ENTER INTO AN EXCLUSIVE
AGREEMENT
TO ENABLE PERSONALIZED THERAPY SELECTION FOR EARLY-STAGE
MELANOMA PATIENTS
Source text for Eikon: ID:nGNX6slwtX
Further company coverage: AKYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akoya Biosciences
See all newsBrief: Akoya Biosciences Inc - On May 20, Receives Unsolicited Acquisition Proposal At $1.40 Per Share From A Third Party- SEC Filing
Akoya Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Akoya Biosciences Q1 Gross Margin 59.3%
Akoya Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview
Leerink Partners downgrades Quanterix to 'market perform' on Akoya deal risks